General Safety of Febuxostat and Allopurinol in a Cardiovascular Outcomes Study in Patients with Gout

被引：0
|
作者：
Saag, Kenneth [1 ]
Becker, Michael A. [2 ]
White, William B. [3 ]
Whelton, Andrew [4 ]
Borer, Jeffrey [5 ]
Gorelick, Philip [6 ]
Hunt, Barbara [7 ]
Castillo, Majin [7 ]
Gunawardhana, Lhanoo [7 ]
机构：
[1] Univ Alabama Birmingham, Birmingham, AL USA
[2] Univ Chicago, Pritzker Sch Med, Chicago, IL 60637 USA
[3] Univ Connecticut, Sch Med, Cardiol, Farmington, CT USA
[4] Johns Hopkins Univ, Sch Med, Hunt Valley, MD USA
[5] Suny Downstate Med Ctr, Brooklyn, NY 11203 USA
[6] Michigan State Univ, Coll Human Med, Grand Rapids, MI USA
[7] Takeda Pharmaceut Int, Deerfield, IL USA
来源：
ARTHRITIS & RHEUMATOLOGY | 2018年 / 70卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
873
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Febuxostat or Allopurinol in Patients with Gout Cardiovascular Safety of Febuxostat and Allopurinol in Patients with Gout and Cardiovascular Morbidities (CARES)
    Alten, R.
    Mischkewitz, M.
    Nitschmann, S.
    [J]. INTERNIST, 2020, 61 (05): : 530 - 532
  • [2] Cardiovascular Safety of Febuxostat or Allopurinol in Patients with Gout
    White, William B.
    Saag, Kenneth G.
    Becker, Michael A.
    Borer, Jeffrey S.
    Gorelick, Philip B.
    Whelton, Andrew
    Hunt, Barbara
    Castillo, Majin
    Gunawardhana, Lhanoo
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2018, 378 (13): : 1200 - 1210
  • [3] CArdiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular ComoRbiditiES
    White, William B.
    Chohan, Saima
    Dabholkar, Aruna
    Hunt, Barbara
    Jackson, Robert
    [J]. AMERICAN HEART JOURNAL, 2012, 164 (01) : 14 - 20
  • [4] Febuxostat vs allopurinol for gout: cardiovascular safety
    [J]. Reactions Weekly, 2021, 1858 (1) : 9 - 9
  • [5] Cardiovascular safety of febuxostat and allopurinol in patients with gout: A meta-analysis
    Guan, Xudong
    Zhang, Shengzhao
    Liu, Jiayan
    Wu, Fengbo
    Zhou, Lingyan
    Liu, Ying
    Su, Na
    [J]. FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [6] Cardiovascular Risk in Gout Patients Cardiovascular Safety of Febuxostat or Allopurinol in Participants with Gout and Cardiovascular Comorbidities (CARES)
    Mueller-Wieland, D.
    Nitschmann, S.
    [J]. INTERNIST, 2018, 59 (11): : 1224 - 1228
  • [7] Cardiovascular Outcomes of Treatment with Febuxostat and Allopurinol in Gout Patients with Kidney Disease
    White, William B.
    Gunawardhana, Lhanoo
    [J]. ARTHRITIS & RHEUMATOLOGY, 2018, 70
  • [8] UPDATE ON COMPARATIVE CARDIOVASCULAR SAFETY OF FEBUXOSTAT VERSUS ALLOPURINOL AMONG PATIENTS WITH GOUT
    Shin, A.
    Ha, Y. J.
    Lee, Y. J.
    Lee, E. B.
    Kang, E. H.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 : 385 - 385
  • [9] Cardiovascular safety associated with febuxostat versus allopurinol among patients with gout: Update with accumulated use of febuxostat
    Shin, Anna
    Choi, Se Rim
    Han, Minji
    Ha, You-Jung
    Lee, Yun Jong
    Lee, Eun Bong
    Kang, Eun Ha
    [J]. SEMINARS IN ARTHRITIS AND RHEUMATISM, 2022, 56
  • [10] The future of febuxostat after the Cardiovascular Safety of Febuxostat and Allopurinol in Patients with Gout and Cardiovascular Morbidities (CARES) trial: who CARES?
    Katsiki, Niki
    Borghi, Claudio
    [J]. EXPERT OPINION ON PHARMACOTHERAPY, 2018, 19 (17) : 1853 - 1856
12345